PPM1D/Wip1 is amplified, overexpressed, and mutated in human non-Hodgkin's lymphomas
Molecular Biology Reports · 2024
DOI: 10.1007/s11033-024-10029-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Hatice Pilevneli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Faculty of Medicine, Aydın Adnan Menderes University, Aytepe Campus, Aydin, Turkey. Hauptthemen laut MEDLINE: Protein Phosphatase 2C, Lymphoma, Non-Hodgkin, Mutation, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 38 Literaturangaben. Gefördert von: TUBITAK.
Abstract (Originalsprache)
BACKGROUND: Wip1, is a p53-dependent Ser/Thr phosphatase involved in the timely termination of DDR. The PPM1D gene encoding Wip1 is deregulated and thus gained an oncogene character in common human solid tumors and cell lines. This study assessed the oncogenic potential of the PPM1D gene in human non- Hodgkin's lymphomas (NHL), the most common hematological malignancy worldwide. METHODS AND RESULTS: FFPE human lymphoid hyperplasia (LH) (n = 17) and NHL tumor lymph node samples (n = 65) and human NHL cell lines were used to assess the oncogenic potential of the PPM1D gene in the present study. Copy number gain and mRNA expression analysis of the PPM1D/Wip1 gene were assessed by qRT-PCR analysis. Mutational analysis of Exon 6 of the PPM1D gene was performed by PCR amplification and Sanger sequencing. Expressions of Wip1 and p53 proteins were assessed by immunohistochemistry and Western blot analysis. CONCLUSIONS: We found that PPM1D gained gene copy number in NHL tumors by 0.7-8 times compared to the control (p < 0.01). Increased PPM1D/Wip1 gene copy number was associated with higher mRNA and protein expression in human NHL samples (p < 0.01). Overexpression of Wip1 in NHL tumors and NHL cell lines was associated with amplification level and was unaffected by p53 status. Furthermore, a heterozygous type insertion mutation was detected in exon 6 (c.1553_1554insA) of the PPM1D gene particularly in DLBCL samples. Wip1 may have oncogenic potential, perhaps playing a role in the onset and progression of human NHL. The possible significance of Wip1 overexpression to chemotherapy response in NHL remains an intriguing question that requires more exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Faculty of Medicine, Aydın Adnan Menderes University, Aytepe Campus, Aydin, Turkey.
- Department of Pathology, Faculty of Medicine, Aydın Adnan Menderes University, Aytepe Campus, Aydin, Turkey.
- Department of Histology and Embryology, Faculty of Veterinary Sciences, Aydın Adnan Menderes University, Aydin, Turkey.
- Department of Medical Biochemistry, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey.
- Department of Medical Biology, Faculty of Medicine, Aydın Adnan Menderes University, Aytepe Campus, Aydin, Turkey. mkilic@adu.edu.tr.
Förderung
- TUBITAK
Zitieren
APA
Pilevneli, H., Döger, F., Karagenç, L., Kozacı, D., & Kilic Eren, M. (2024). PPM1D/Wip1 is amplified, overexpressed, and mutated in human non-Hodgkin's lymphomas. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-10029-2
Vancouver
Pilevneli H, Döger F, Karagenç L, Kozacı D, Kilic Eren M. PPM1D/Wip1 is amplified, overexpressed, and mutated in human non-Hodgkin's lymphomas. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-10029-2
BibTeX
@article{Pilevneli2024,
author = {Pilevneli, Hatice and Döger, Firuzan and Karagenç, Levent and Kozacı, Didem and Kilic Eren, Mehtap},
title = {PPM1D/Wip1 is amplified, overexpressed, and mutated in human non-Hodgkin's lymphomas},
journal = {Molecular Biology Reports},
year = {2024},
doi = {10.1007/s11033-024-10029-2}
}
EUVIMED